FHIR IG analytics| Package | de.medizininformatikinitiative.kerndatensatz.onkologie |
| Resource Type | ConceptMap |
| Id | ConceptMap-mii-cm-onko-atc-transitions-2021.json |
| FHIR Version | R4 |
| Source | https://medizininformatik-initiative.github.io/kerndatensatzmodul-onkologie/2027.0.0-ballot.1/ConceptMap-mii-cm-onko-atc-transitions-2021.html |
| URL | https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2021 |
| Version | 2027.0.0-ballot.1 |
| Status | active |
| Date | 2024-12-12 |
| Name | MII_CM_Onko_ATC_Transitions_2021 |
| Title | MII CM Onko ATC Code Changes 2020 to 2021 |
| Realm | de |
| Description | Diese ConceptMap dokumentiert ausschließlich die ATC-Code-Änderungen von 2020 zu 2021. Im Jahr 2021 erfolgte eine umfassende Reorganisation der ATC-Klassifikation für onkologische Substanzen mit Umkodierung von über 60 Wirkstoffen. |
| Purpose | Migration von ATC-Codes für Substanzen, die 2021 umkodiert wurden. Enthält nur geänderte Codes, keine neuen oder unveränderten Einträge. |
No resources found
| CodeSystem | ||
| de.fhir.terminologie-basis#1.0.0-alpha1 | atc | ATC |
| ValueSet | ||
| de.medizininformatikinitiative.kerndatensatz.onkologie#2027.0.0-ballot.1 | mii-vs-onko-systemische-therapie-substanzen-2020 | MII VS Onkologie Systemische Therapie Substanzen ATC 2020 |
| de.medizininformatikinitiative.kerndatensatz.onkologie#2027.0.0-ballot.1 | mii-vs-onko-systemische-therapie-substanzen-2021 | MII VS Onkologie Systemische Therapie Substanzen ATC 2021 |
Note: links and images are rebased to the (stated) source
English
Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2021
Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2020 to MII VS Onkologie Systemische Therapie Substanzen ATC 2021
Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)
| Source Code | Relationship | Target Code | Comment |
| L01XE01 (Imatinib) | is equivalent to | L01EA01 (Imatinib) | Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren |
| L01XE06 (Dasatinib) | is equivalent to | L01EA02 (Dasatinib) | |
| L01XE08 (Nilotinib) | is equivalent to | L01EA03 (Nilotinib) | |
| L01XE14 (Bosutinib) | is equivalent to | L01EA04 (Bosutinib) | |
| L01XE24 (Ponatinib) | is equivalent to | L01EA05 (Ponatinib) | |
| L01XE02 (Gefitinib) | is equivalent to | L01EB01 (Gefitinib) | Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren |
| L01XE03 (Erlotinib) | is equivalent to | L01EB02 (Erlotinib) | |
| L01XE13 (Afatinib) | is equivalent to | L01EB03 (Afatinib) | |
| L01XE35 (Osimertinib) | is equivalent to | L01EB04 (Osimertinib) | |
| L01XE15 (Vemurafenib) | is equivalent to | L01EC01 (Vemurafenib) | Reklassifizierung zu BRAF-Inhibitoren |
| L01XE23 (Dabrafenib) | is equivalent to | L01EC02 (Dabrafenib) | |
| L01XE46 (Encorafenib) | is equivalent to | L01EC03 (Encorafenib) | |
| L01XE16 (Crizotinib) | is equivalent to | L01ED01 (Crizotinib) | Reklassifizierung zu ALK-Inhibitoren |
| L01XE28 (Ceritinib) | is equivalent to | L01ED02 (Ceritinib) | |
| L01XE36 (Alectinib) | is equivalent to | L01ED03 (Alectinib) | |
| L01XE43 (Brigatinib) | is equivalent to | L01ED04 (Brigatinib) | |
| L01XE44 (Lorlatinib) | is equivalent to | L01ED05 (Lorlatinib) | |
| L01XE25 (Trametinib) | is equivalent to | L01EE01 (Trametinib) | Reklassifizierung zu MEK-Inhibitoren |
| L01XE38 (Cobimetinib) | is equivalent to | L01EE02 (Cobimetinib) | |
| L01XE41 (Binimetinib) | is equivalent to | L01EE03 (Binimetinib) | |
| L01XE33 (Palbociclib) | is equivalent to | L01EF01 (Palbociclib) | Reklassifizierung zu CDK4/6-Inhibitoren |
| L01XE42 (Ribociclib) | is equivalent to | L01EF02 (Ribociclib) | |
| L01XE50 (Abemaciclib) | is equivalent to | L01EF03 (Abemaciclib) | |
| L01XE09 (Temsirolimus) | is equivalent to | L01EG01 (Temsirolimus) | Reklassifizierung zu mTOR-Inhibitoren |
| L01XE10 (Everolimus) | is equivalent to | L01EG02 (Everolimus) | |
| L01XE07 (Lapatinib) | is equivalent to | L01EH01 (Lapatinib) | Reklassifizierung zu HER2-Inhibitoren |
| L01XE45 (Neratinib) | is equivalent to | L01EH02 (Neratinib) | |
| L01XE18 (Ruxolitinib) | is equivalent to | L01EJ01 (Ruxolitinib) | Reklassifizierung zu JAK-Inhibitoren |
| L01XE17 (Axitinib) | is equivalent to | L01EK01 (Axitinib) | Reklassifizierung zu VEGFR-Inhibitoren |
| L01XE34 (Tivozanib) | is equivalent to | L01EK03 (Tivozanib) | |
| L01XE27 (Ibrutinib) | is equivalent to | L01EL01 (Ibrutinib) | Reklassifizierung zu BTK-Inhibitoren |
| L01XE51 (Acalabrutinib) | is equivalent to | L01EL02 (Acalabrutinib) | |
| L01XX47 (Idelalisib) | is equivalent to | L01EM01 (Idelalisib) | Reklassifizierung zu PI3K-Inhibitoren |
| L01XX61 (Copanlisib) | is equivalent to | L01EM02 (Copanlisib) | |
| L01XE04 (Sunitinib) | is equivalent to | L01EX01 (Sunitinib) | Reklassifizierung zu andere Proteinkinase-Inhibitoren |
| L01XE05 (Sorafenib) | is equivalent to | L01EX02 (Sorafenib) | |
| L01XE12 (Vandetanib) | is equivalent to | L01EX04 (Vandetanib) | |
| L01XE21 (Regorafenib) | is equivalent to | L01EX05 (Regorafenib) | |
| L01XE26 (Cabozantinib) | is equivalent to | L01EX07 (Cabozantinib) | |
| L01XE29 (Lenvatinib) | is equivalent to | L01EX08 (Lenvatinib) | |
| L01XE31 (Nintedanib) | is equivalent to | L01EX09 (Nintedanib) | |
| L01XE39 (Midostaurin) | is equivalent to | L01EX10 (Midostaurin) | |
| L01XE52 (Quizartinib) | is equivalent to | L01EX11 (Quizartinib) | |
| L01XE53 (Larotrectinib) | is equivalent to | L01EX12 (Larotrectinib) | |
| L01XE54 (Gilteritinib) | is equivalent to | L01EX13 (Gilteritinib) | |
| L01XX14 (Tretinoin) | is equivalent to | L01XF01 (Tretinoin) | Reklassifizierung zu Retinoide |
| L01XX22 (Alitretinoin) | is equivalent to | L01XF02 (Alitretinoin) | |
| L01XX25 (Bexaroten) | is equivalent to | L01XF03 (Bexaroten) | |
| L01XX32 (Bortezomib) | is equivalent to | L01XG01 (Bortezomib) | Reklassifizierung zu Proteasom-Inhibitoren |
| L01XX45 (Carfilzomib) | is equivalent to | L01XG02 (Carfilzomib) | |
| L01XX50 (Ixazomib) | is equivalent to | L01XG03 (Ixazomib) | |
| L01XX38 (Vorinostat) | is equivalent to | L01XH01 (Vorinostat) | Reklassifizierung zu Histon-Deacetylase-Inhibitoren |
| L01XX39 (Romidepsin) | is equivalent to | L01XH02 (Romidepsin) | |
| L01XX42 (Panobinostat) | is equivalent to | L01XH03 (Panobinostat) | |
| L01XX49 (Belinostat) | is equivalent to | L01XH04 (Belinostat) | |
| L01XX43 (Vismodegib) | is equivalent to | L01XJ01 (Vismodegib) | Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren |
| L01XX63 (Glasdegib) | is equivalent to | L01XJ03 (Glasdegib) | |
| L01XX46 (Olaparib) | is equivalent to | L01XK01 (Olaparib) | Reklassifizierung zu PARP-Inhibitoren |
| L01XX54 (Niraparib) | is equivalent to | L01XK02 (Niraparib) | |
| L01XX60 (Talazoparib) | is equivalent to | L01XK04 (Talazoparib) | |
| L01XX17 (Topotecan) | is equivalent to | L01CE01 (Topotecan) | Reklassifizierung zu Topoisomerase-I-Inhibitoren |
| L01XX19 (Irinotecan) | is equivalent to | L01CE02 (Irinotecan) |
German
Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2021
Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2020 to MII VS Onkologie Systemische Therapie Substanzen ATC 2021
Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)
| Source Code | Relationship | Target Code | Comment |
| L01XE01 (Imatinib) | is equivalent to | L01EA01 (Imatinib) | Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren |
| L01XE06 (Dasatinib) | is equivalent to | L01EA02 (Dasatinib) | |
| L01XE08 (Nilotinib) | is equivalent to | L01EA03 (Nilotinib) | |
| L01XE14 (Bosutinib) | is equivalent to | L01EA04 (Bosutinib) | |
| L01XE24 (Ponatinib) | is equivalent to | L01EA05 (Ponatinib) | |
| L01XE02 (Gefitinib) | is equivalent to | L01EB01 (Gefitinib) | Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren |
| L01XE03 (Erlotinib) | is equivalent to | L01EB02 (Erlotinib) | |
| L01XE13 (Afatinib) | is equivalent to | L01EB03 (Afatinib) | |
| L01XE35 (Osimertinib) | is equivalent to | L01EB04 (Osimertinib) | |
| L01XE15 (Vemurafenib) | is equivalent to | L01EC01 (Vemurafenib) | Reklassifizierung zu BRAF-Inhibitoren |
| L01XE23 (Dabrafenib) | is equivalent to | L01EC02 (Dabrafenib) | |
| L01XE46 (Encorafenib) | is equivalent to | L01EC03 (Encorafenib) | |
| L01XE16 (Crizotinib) | is equivalent to | L01ED01 (Crizotinib) | Reklassifizierung zu ALK-Inhibitoren |
| L01XE28 (Ceritinib) | is equivalent to | L01ED02 (Ceritinib) | |
| L01XE36 (Alectinib) | is equivalent to | L01ED03 (Alectinib) | |
| L01XE43 (Brigatinib) | is equivalent to | L01ED04 (Brigatinib) | |
| L01XE44 (Lorlatinib) | is equivalent to | L01ED05 (Lorlatinib) | |
| L01XE25 (Trametinib) | is equivalent to | L01EE01 (Trametinib) | Reklassifizierung zu MEK-Inhibitoren |
| L01XE38 (Cobimetinib) | is equivalent to | L01EE02 (Cobimetinib) | |
| L01XE41 (Binimetinib) | is equivalent to | L01EE03 (Binimetinib) | |
| L01XE33 (Palbociclib) | is equivalent to | L01EF01 (Palbociclib) | Reklassifizierung zu CDK4/6-Inhibitoren |
| L01XE42 (Ribociclib) | is equivalent to | L01EF02 (Ribociclib) | |
| L01XE50 (Abemaciclib) | is equivalent to | L01EF03 (Abemaciclib) | |
| L01XE09 (Temsirolimus) | is equivalent to | L01EG01 (Temsirolimus) | Reklassifizierung zu mTOR-Inhibitoren |
| L01XE10 (Everolimus) | is equivalent to | L01EG02 (Everolimus) | |
| L01XE07 (Lapatinib) | is equivalent to | L01EH01 (Lapatinib) | Reklassifizierung zu HER2-Inhibitoren |
| L01XE45 (Neratinib) | is equivalent to | L01EH02 (Neratinib) | |
| L01XE18 (Ruxolitinib) | is equivalent to | L01EJ01 (Ruxolitinib) | Reklassifizierung zu JAK-Inhibitoren |
| L01XE17 (Axitinib) | is equivalent to | L01EK01 (Axitinib) | Reklassifizierung zu VEGFR-Inhibitoren |
| L01XE34 (Tivozanib) | is equivalent to | L01EK03 (Tivozanib) | |
| L01XE27 (Ibrutinib) | is equivalent to | L01EL01 (Ibrutinib) | Reklassifizierung zu BTK-Inhibitoren |
| L01XE51 (Acalabrutinib) | is equivalent to | L01EL02 (Acalabrutinib) | |
| L01XX47 (Idelalisib) | is equivalent to | L01EM01 (Idelalisib) | Reklassifizierung zu PI3K-Inhibitoren |
| L01XX61 (Copanlisib) | is equivalent to | L01EM02 (Copanlisib) | |
| L01XE04 (Sunitinib) | is equivalent to | L01EX01 (Sunitinib) | Reklassifizierung zu andere Proteinkinase-Inhibitoren |
| L01XE05 (Sorafenib) | is equivalent to | L01EX02 (Sorafenib) | |
| L01XE12 (Vandetanib) | is equivalent to | L01EX04 (Vandetanib) | |
| L01XE21 (Regorafenib) | is equivalent to | L01EX05 (Regorafenib) | |
| L01XE26 (Cabozantinib) | is equivalent to | L01EX07 (Cabozantinib) | |
| L01XE29 (Lenvatinib) | is equivalent to | L01EX08 (Lenvatinib) | |
| L01XE31 (Nintedanib) | is equivalent to | L01EX09 (Nintedanib) | |
| L01XE39 (Midostaurin) | is equivalent to | L01EX10 (Midostaurin) | |
| L01XE52 (Quizartinib) | is equivalent to | L01EX11 (Quizartinib) | |
| L01XE53 (Larotrectinib) | is equivalent to | L01EX12 (Larotrectinib) | |
| L01XE54 (Gilteritinib) | is equivalent to | L01EX13 (Gilteritinib) | |
| L01XX14 (Tretinoin) | is equivalent to | L01XF01 (Tretinoin) | Reklassifizierung zu Retinoide |
| L01XX22 (Alitretinoin) | is equivalent to | L01XF02 (Alitretinoin) | |
| L01XX25 (Bexaroten) | is equivalent to | L01XF03 (Bexaroten) | |
| L01XX32 (Bortezomib) | is equivalent to | L01XG01 (Bortezomib) | Reklassifizierung zu Proteasom-Inhibitoren |
| L01XX45 (Carfilzomib) | is equivalent to | L01XG02 (Carfilzomib) | |
| L01XX50 (Ixazomib) | is equivalent to | L01XG03 (Ixazomib) | |
| L01XX38 (Vorinostat) | is equivalent to | L01XH01 (Vorinostat) | Reklassifizierung zu Histon-Deacetylase-Inhibitoren |
| L01XX39 (Romidepsin) | is equivalent to | L01XH02 (Romidepsin) | |
| L01XX42 (Panobinostat) | is equivalent to | L01XH03 (Panobinostat) | |
| L01XX49 (Belinostat) | is equivalent to | L01XH04 (Belinostat) | |
| L01XX43 (Vismodegib) | is equivalent to | L01XJ01 (Vismodegib) | Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren |
| L01XX63 (Glasdegib) | is equivalent to | L01XJ03 (Glasdegib) | |
| L01XX46 (Olaparib) | is equivalent to | L01XK01 (Olaparib) | Reklassifizierung zu PARP-Inhibitoren |
| L01XX54 (Niraparib) | is equivalent to | L01XK02 (Niraparib) | |
| L01XX60 (Talazoparib) | is equivalent to | L01XK04 (Talazoparib) | |
| L01XX17 (Topotecan) | is equivalent to | L01CE01 (Topotecan) | Reklassifizierung zu Topoisomerase-I-Inhibitoren |
| L01XX19 (Irinotecan) | is equivalent to | L01CE02 (Irinotecan) |
{
"resourceType": "ConceptMap",
"id": "mii-cm-onko-atc-transitions-2021",
"meta": {
"extension": [
{
"url": "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
"valueCode": "CC-BY-4.0"
},
{
"extension": [
{
"url": "packageId",
"valueId": "de.medizininformatikinitiative.kerndatensatz.onkologie"
},
{
"url": "version",
"valueString": "2027.0.0-ballot.1"
},
{
"url": "uri",
"valueUri": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
}
],
"url": "http://hl7.org/fhir/StructureDefinition/package-source"
}
],
"profile": [
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap",
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"
]
},
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode": "shareable"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode": "publishable"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
"code": "package",
"display": "Package"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
"valueDate": "2026-09-15"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-topic",
"valueCodeableConcept": {
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C3262"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail": {
"telecom": [
{
"system": "email",
"value": "thomas.debertshaeuser@charite.de"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-editor",
"valueContactDetail": {
"name": "Taskforce Core Data Set"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail": {
"name": "Interoperability Working Group",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail": {
"name": "National Steering Committee",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail": {
"name": "Interoperability Working Group",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail": {
"name": "National Steering Committee",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
"valueCoding": {
"system": "http://hl7.org/fhir/version-algorithm",
"code": "semver",
"display": "SemVer"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
"valuePeriod": {
"start": "2027"
}
}
],
"url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2021",
"version": "2027.0.0-ballot.1",
"name": "MII_CM_Onko_ATC_Transitions_2021",
"title": "MII CM Onko ATC Code Changes 2020 to 2021",
"status": "active",
"experimental": false,
"date": "2024-12-12",
"publisher": "Medizininformatik Initiative",
"contact": [
{
"name": "Medizininformatik Initiative",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/"
}
]
}
],
"description": "Diese ConceptMap dokumentiert ausschließlich die ATC-Code-Änderungen von 2020 zu 2021. Im Jahr 2021 erfolgte eine umfassende Reorganisation der ATC-Klassifikation für onkologische Substanzen mit Umkodierung von über 60 Wirkstoffen.",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "DE",
"display": "Germany"
}
]
}
],
"purpose": "Migration von ATC-Codes für Substanzen, die 2021 umkodiert wurden. Enthält nur geänderte Codes, keine neuen oder unveränderten Einträge.",
"sourceCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2020",
"targetCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021",
"group": [
{
"source": "http://fhir.de/CodeSystem/bfarm/atc",
"target": "http://fhir.de/CodeSystem/bfarm/atc",
"element": [
{
"code": "L01XE01",
"display": "Imatinib",
"target": [
{
"code": "L01EA01",
"display": "Imatinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren"
}
]
},
{
"code": "L01XE06",
"display": "Dasatinib",
"target": [
{
"code": "L01EA02",
"display": "Dasatinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE08",
"display": "Nilotinib",
"target": [
{
"code": "L01EA03",
"display": "Nilotinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE14",
"display": "Bosutinib",
"target": [
{
"code": "L01EA04",
"display": "Bosutinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE24",
"display": "Ponatinib",
"target": [
{
"code": "L01EA05",
"display": "Ponatinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE02",
"display": "Gefitinib",
"target": [
{
"code": "L01EB01",
"display": "Gefitinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren"
}
]
},
{
"code": "L01XE03",
"display": "Erlotinib",
"target": [
{
"code": "L01EB02",
"display": "Erlotinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE13",
"display": "Afatinib",
"target": [
{
"code": "L01EB03",
"display": "Afatinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE35",
"display": "Osimertinib",
"target": [
{
"code": "L01EB04",
"display": "Osimertinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE15",
"display": "Vemurafenib",
"target": [
{
"code": "L01EC01",
"display": "Vemurafenib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu BRAF-Inhibitoren"
}
]
},
{
"code": "L01XE23",
"display": "Dabrafenib",
"target": [
{
"code": "L01EC02",
"display": "Dabrafenib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE46",
"display": "Encorafenib",
"target": [
{
"code": "L01EC03",
"display": "Encorafenib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE16",
"display": "Crizotinib",
"target": [
{
"code": "L01ED01",
"display": "Crizotinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu ALK-Inhibitoren"
}
]
},
{
"code": "L01XE28",
"display": "Ceritinib",
"target": [
{
"code": "L01ED02",
"display": "Ceritinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE36",
"display": "Alectinib",
"target": [
{
"code": "L01ED03",
"display": "Alectinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE43",
"display": "Brigatinib",
"target": [
{
"code": "L01ED04",
"display": "Brigatinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE44",
"display": "Lorlatinib",
"target": [
{
"code": "L01ED05",
"display": "Lorlatinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE25",
"display": "Trametinib",
"target": [
{
"code": "L01EE01",
"display": "Trametinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu MEK-Inhibitoren"
}
]
},
{
"code": "L01XE38",
"display": "Cobimetinib",
"target": [
{
"code": "L01EE02",
"display": "Cobimetinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE41",
"display": "Binimetinib",
"target": [
{
"code": "L01EE03",
"display": "Binimetinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE33",
"display": "Palbociclib",
"target": [
{
"code": "L01EF01",
"display": "Palbociclib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu CDK4/6-Inhibitoren"
}
]
},
{
"code": "L01XE42",
"display": "Ribociclib",
"target": [
{
"code": "L01EF02",
"display": "Ribociclib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE50",
"display": "Abemaciclib",
"target": [
{
"code": "L01EF03",
"display": "Abemaciclib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE09",
"display": "Temsirolimus",
"target": [
{
"code": "L01EG01",
"display": "Temsirolimus",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu mTOR-Inhibitoren"
}
]
},
{
"code": "L01XE10",
"display": "Everolimus",
"target": [
{
"code": "L01EG02",
"display": "Everolimus",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE07",
"display": "Lapatinib",
"target": [
{
"code": "L01EH01",
"display": "Lapatinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu HER2-Inhibitoren"
}
]
},
{
"code": "L01XE45",
"display": "Neratinib",
"target": [
{
"code": "L01EH02",
"display": "Neratinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE18",
"display": "Ruxolitinib",
"target": [
{
"code": "L01EJ01",
"display": "Ruxolitinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu JAK-Inhibitoren"
}
]
},
{
"code": "L01XE17",
"display": "Axitinib",
"target": [
{
"code": "L01EK01",
"display": "Axitinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu VEGFR-Inhibitoren"
}
]
},
{
"code": "L01XE34",
"display": "Tivozanib",
"target": [
{
"code": "L01EK03",
"display": "Tivozanib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE27",
"display": "Ibrutinib",
"target": [
{
"code": "L01EL01",
"display": "Ibrutinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu BTK-Inhibitoren"
}
]
},
{
"code": "L01XE51",
"display": "Acalabrutinib",
"target": [
{
"code": "L01EL02",
"display": "Acalabrutinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX47",
"display": "Idelalisib",
"target": [
{
"code": "L01EM01",
"display": "Idelalisib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu PI3K-Inhibitoren"
}
]
},
{
"code": "L01XX61",
"display": "Copanlisib",
"target": [
{
"code": "L01EM02",
"display": "Copanlisib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE04",
"display": "Sunitinib",
"target": [
{
"code": "L01EX01",
"display": "Sunitinib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu andere Proteinkinase-Inhibitoren"
}
]
},
{
"code": "L01XE05",
"display": "Sorafenib",
"target": [
{
"code": "L01EX02",
"display": "Sorafenib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE12",
"display": "Vandetanib",
"target": [
{
"code": "L01EX04",
"display": "Vandetanib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE21",
"display": "Regorafenib",
"target": [
{
"code": "L01EX05",
"display": "Regorafenib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE26",
"display": "Cabozantinib",
"target": [
{
"code": "L01EX07",
"display": "Cabozantinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE29",
"display": "Lenvatinib",
"target": [
{
"code": "L01EX08",
"display": "Lenvatinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE31",
"display": "Nintedanib",
"target": [
{
"code": "L01EX09",
"display": "Nintedanib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE39",
"display": "Midostaurin",
"target": [
{
"code": "L01EX10",
"display": "Midostaurin",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE52",
"display": "Quizartinib",
"target": [
{
"code": "L01EX11",
"display": "Quizartinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE53",
"display": "Larotrectinib",
"target": [
{
"code": "L01EX12",
"display": "Larotrectinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XE54",
"display": "Gilteritinib",
"target": [
{
"code": "L01EX13",
"display": "Gilteritinib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX14",
"display": "Tretinoin",
"target": [
{
"code": "L01XF01",
"display": "Tretinoin",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Retinoide"
}
]
},
{
"code": "L01XX22",
"display": "Alitretinoin",
"target": [
{
"code": "L01XF02",
"display": "Alitretinoin",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX25",
"display": "Bexaroten",
"target": [
{
"code": "L01XF03",
"display": "Bexaroten",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX32",
"display": "Bortezomib",
"target": [
{
"code": "L01XG01",
"display": "Bortezomib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Proteasom-Inhibitoren"
}
]
},
{
"code": "L01XX45",
"display": "Carfilzomib",
"target": [
{
"code": "L01XG02",
"display": "Carfilzomib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX50",
"display": "Ixazomib",
"target": [
{
"code": "L01XG03",
"display": "Ixazomib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX38",
"display": "Vorinostat",
"target": [
{
"code": "L01XH01",
"display": "Vorinostat",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Histon-Deacetylase-Inhibitoren"
}
]
},
{
"code": "L01XX39",
"display": "Romidepsin",
"target": [
{
"code": "L01XH02",
"display": "Romidepsin",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX42",
"display": "Panobinostat",
"target": [
{
"code": "L01XH03",
"display": "Panobinostat",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX49",
"display": "Belinostat",
"target": [
{
"code": "L01XH04",
"display": "Belinostat",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX43",
"display": "Vismodegib",
"target": [
{
"code": "L01XJ01",
"display": "Vismodegib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren"
}
]
},
{
"code": "L01XX63",
"display": "Glasdegib",
"target": [
{
"code": "L01XJ03",
"display": "Glasdegib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX46",
"display": "Olaparib",
"target": [
{
"code": "L01XK01",
"display": "Olaparib",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu PARP-Inhibitoren"
}
]
},
{
"code": "L01XX54",
"display": "Niraparib",
"target": [
{
"code": "L01XK02",
"display": "Niraparib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX60",
"display": "Talazoparib",
"target": [
{
"code": "L01XK04",
"display": "Talazoparib",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XX17",
"display": "Topotecan",
"target": [
{
"code": "L01CE01",
"display": "Topotecan",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Topoisomerase-I-Inhibitoren"
}
]
},
{
"code": "L01XX19",
"display": "Irinotecan",
"target": [
{
"code": "L01CE02",
"display": "Irinotecan",
"equivalence": "equivalent"
}
]
}
]
}
]
}